T. Rowe Price Associates
ELGX

T. Rowe Price Associates’s Endologix Inc ELGX Stock Holding History

T. Rowe Price Associates’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-87,763
Closed -$6.35M – 2593
2017
Q1 		$6.35M Sell
87,763
-11,547
-12% -$764K ﹤0.01% 1399
2016
Q4 		$5.68M Sell
99,310
-5,510
-5% -$505K ﹤0.01% 1403
2016
Q3 		$13.4M Buy
104,820
+99,790
+1,984% +$12.8M ﹤0.01% 1250
2016
Q2 		$627K Hold
5,030
– – ﹤0.01% 1878
2016
Q1 		$421K Buy
5,030
+1,110
+28% +$91.5K ﹤0.01% 2043
2015
Q4 		$388K Buy
3,920
+1,450
+59% +$155K ﹤0.01% 2063
2015
Q3 		$303K Hold
2,470
– – ﹤0.01% 2137
2015
Q2 		$379K Hold
2,470
– – ﹤0.01% 2115
2015
Q1 		$422K Hold
2,470
– – ﹤0.01% 2050
2014
Q4 		$378K Hold
2,470
– – ﹤0.01% 2074
2014
Q3 		$262K Hold
2,470
– – ﹤0.01% 2211
2014
Q2 		$376K Hold
2,470
– – ﹤0.01% 2067
2014
Q1 		$318K Hold
2,470
– – ﹤0.01% 2131
2013
Q4 		$431K Hold
2,470
– – ﹤0.01% 1972
2013
Q3 		$398K Hold
2,470
– – ﹤0.01% 1980
2013
Q2 		$328K Buy
+2,470
New +$349K ﹤0.01% 2036

Other funds holding ELGX

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

T. Rowe Price Associates's ELGX Position: Q2 2017 in Review

T. Rowe Price Associates sold out of Endologix Inc (ELGX) in Q2 2017, closing a stake of 87,763 shares — an estimated $6.35M sold.

T. Rowe Price Associates first reported a position in ELGX in Q2 2013 and held it in 16 quarters. The position peaked at $13.4M in Q3 2016. 111 funds tracked by Wall St. Rank hold ELGX as of Q2 2017.

  • T. Rowe Price Associates reported no remaining Endologix Inc position as of Q2 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 87,763 Endologix Inc shares in Q2 2017, an estimated $6.35M.
  • T. Rowe Price Associates first reported a position in Endologix Inc in Q2 2013 and held it in 16 quarters.
  • T. Rowe Price Associates's Endologix Inc position peaked at $13.4M in Q3 2016.
  • 111 funds tracked by Wall St. Rank held Endologix Inc as of Q2 2017.

Based on T. Rowe Price Associates's 13F filing for Q2 2017, filed 14 Aug 2017.